EN DE
Watch Mercury Biopharmaceutical Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Mercury Biopharmaceutical Corporation (6932) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Mercury Biopharmaceutical Corporation stock TWD 2.09, price TWD 5.49, that is 61.9% below the price, quality 40 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

MB Mercury Biopharmaceutical Corporation logo Thin data Nov 10, 2026

Mercury Biopharmaceutical Corporation

6932 · TWO
Very expensive, weak quality

Our calculation puts a fair price 62% below what the stock costs today.

Low debt
Quality 40/100
Revenue last quarter 76% below a year ago.
Fair value 2.09 TWD · Strongly overvalued
Weak Growth
Negative free cash flow
Trails peers (0/8)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Mercury Biopharmaceutical Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

27.28 TWD 4.92 TWD Fair Value 2.09 TWD Dec 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

47‑month range 4.92 TWD – 27.28 TWD · fair‑value band 1.56 TWD – 2.61 TWD · the 5.49 TWD price screens above the 2.09 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Mercury Biopharmaceutical in your weekly email

Every Wednesday you see whether Mercury Biopharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan.

Show moreShow less

The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development.

It also offers formulation design and 3D pharmaceutical processing services. Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei City, Taiwan.

Stock analysis

Mercury Biopharmaceutical Corporation (6932) currently trades at 5.49 TWD, while our estimate is 2.09 TWD, 62% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1.56 TWD (bear) to 2.61 TWD (bull), the price of 5.49 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Mercury Biopharmaceutical Corporation reported revenue of 0 TWD in FY2025 versus 0 TWD in FY2021. Reported net income was −67.2M TWD in FY2025.

Key figures

Market cap 2.3B TWD (≈ $71.0M) Micro · EPS (TTM) −0.1200 TWD · Return on equity −22.8% · Return on assets (EBIT) −20.6% (5-year average) · Revenue (TTM) 246K TWD · Revenue growth (YoY) −76.2% · Free cash flow −58.1M TWD · Net cash 1.9M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −62%, 6932 screens richer than that median.

Fair Value

Bear 1.56 TWD Fair Value 2.09 TWD Bull 2.61 TWD
Price 5.49 TWD · Downside -61.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 14
Are margins and returns getting better?
Cashflow 17
Do the profits arrive as real cash?
Financial strength 89
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 37
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 21
Distance to the 52-week high, does not count
New shares 68
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6932 screens overvalued: fair value 62% below the price. Compare with Merck KGaA →

Compare Mercury Biopharmaceutical Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 609 stocks

Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −60.0% · Bottom 25%
Profitability
Return on assets −24.2% · Bottom 25%
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) −76.2% · Bottom 25%
Balance sheet
Debt / equity 0.17× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 10.10× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)0 · sector 24
PAST (return on equity)0 · sector 25
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.32 $113.53 +38% vs 6932
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥49.23 ¥55.21 +12% vs 6932
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs 6932
Haleon plc HLN $8.97 $8.62 −4% vs 6932
Merck KGaA MRK €149.20 €109.18 −27% vs 6932
Galderma Group GALD CHF 190.65 CHF 109.80 −42% vs 6932
Takeda Pharmaceutical Company TAK $21.09 $11.31 −46% vs 6932
Teva Pharmaceutical Industries Limited TEVA $42.97 $20.74 −52% vs 6932
Sandoz Group SDZ CHF 84.46 CHF 39.70 −53% vs 6932
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 6932

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mercury Biopharmaceutical Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Mercury Biopharmaceutical Corporation Fair Value". https://www.fairvalue-calculator.com/stock/6932

Frequently asked questions

Is Mercury Biopharmaceutical Corporation (6932) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 2.09 TWD versus a price of 5.49 TWD, about 62% lower (overvalued).
What is the fair value of 6932?
Our estimate for Mercury Biopharmaceutical Corporation is 2.09 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 5.49 TWD.
What is the quality score of 6932?
Mercury Biopharmaceutical Corporation has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mercury Biopharmaceutical Corporation (6932)?
Our calculated price target is the estimate of 2.09 TWD (as of Nov 10, 2026). Cautious scenario 1.56 TWD, optimistic scenario 2.61 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Mercury Biopharmaceutical Corporation stock forecast for 2026?
Our estimate puts fair value at 2.09 TWD, about 62% lower versus a price of 5.49 TWD (overvalued). Cautious scenario 1.56 TWD, optimistic scenario 2.61 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Mercury Biopharmaceutical Corporation (6932)?
Mercury Biopharmaceutical Corporation reported trailing-twelve-month revenue of about 246K TWD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Mercury Biopharmaceutical Corporation (6932)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mercury Biopharmaceutical Corporation it is 2.09 TWD per share (as of Nov 10, 2026), against a price of 5.49 TWD.
Is Mercury Biopharmaceutical Corporation stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 6932 trades above its calculated fair value: price 5.49 TWD, fair value 2.09 TWD, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6932?
No. The price is what the market pays today (5.49 TWD); the fair value is what the company's own numbers justify (2.09 TWD). For Mercury Biopharmaceutical Corporation the two are 3.40 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Mercury Biopharmaceutical Corporation worth?
The market values Mercury Biopharmaceutical Corporation at about 2.3B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 5.49 TWD; our models calculate a fair value of 2.09 TWD per share.
What do the bullish and bearish scenarios say about 6932?
Our models span a range for Mercury Biopharmaceutical Corporation: cautious scenario 1.56 TWD, base 2.09 TWD, optimistic 2.61 TWD per share (as of Nov 10, 2026, price 5.49 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mercury Biopharmaceutical Corporation (6932)?
Balance-sheet figures for Mercury Biopharmaceutical Corporation (as of Nov 10, 2026): return on equity −22.8%, debt of 0.17 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 6932 from its 52-week high?
Mercury Biopharmaceutical Corporation trades at 5.49 TWD, about 52% below its 52-week high of 11.45 TWD and 12% above the low of 4.92 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 2.09 TWD is for.
Which stocks are comparable to Mercury Biopharmaceutical Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mercury Biopharmaceutical Corporation stock attractive at the current price?
The data as of Nov 10, 2026: price 5.49 TWD, calculated fair value 2.09 TWD (−62%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Mercury Biopharmaceutical Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mercury Biopharmaceutical Corporation (6932)?
The closing price on Nov 10, 2026 was 5.49 TWD. Our estimate is 2.09 TWD, about 62% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mercury Biopharmaceutical Corporation right now?
The price sits above even our optimistic bull case (2.61 TWD). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Mercury Biopharmaceutical Corporation

How large is the market capitalisation of Mercury Biopharmaceutical Corporation (6932)?
The market capitalisation of Mercury Biopharmaceutical Corporation is 2.3B TWD (≈ $71.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Mercury Biopharmaceutical Corporation (6932)?
Earnings per share at Mercury Biopharmaceutical Corporation are −0.1200 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Mercury Biopharmaceutical Corporation (6932)?
The return on equity (ROE) of Mercury Biopharmaceutical Corporation is −22.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mercury Biopharmaceutical Corporation (6932)?
On an EBIT basis the return on assets of Mercury Biopharmaceutical Corporation is −20.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Mercury Biopharmaceutical Corporation (6932)?
Revenue at Mercury Biopharmaceutical Corporation is growing −76.2% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Mercury Biopharmaceutical Corporation (6932) generate?
The free cash flow of Mercury Biopharmaceutical Corporation is −58.1M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Mercury Biopharmaceutical Corporation (6932) hold?
Mercury Biopharmaceutical Corporation holds more cash than debt, 1.9M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Mercury Biopharmaceutical Corporation in the live analysis

One click puts Mercury Biopharmaceutical Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.